🔎 Trials Near Me

ホーム › 急性骨髄性白血病 › ニュージャージー

ニュージャージーにおける急性骨髄性白血病の臨床試験

ニュージャージー内の拠点で、急性骨髄性白血病に関する32件の研究が参加者を募集しています。

ニュージャージー内の都市

公式研究テキスト(英語)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Englewood Hospital and Medical Center, Englewood
  • Hackettstown Medical Center, Hackettstown
  • Morristown Medical Center, Morristown
  • 他6件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Memorial Sloan Kettering Monmouth, Middletown
  • Memorial Sloan Kettering Bergen, Montvale
  • 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06484062

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
被験者募集中第1相
12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooperman Barnabas Medical Center, Livingston
  • Monmouth Medical Center, Long Branch
  • 他6件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooper Hospital University Medical Center, Camden
  • Cooperman Barnabas Medical Center, Livingston
  • 他7件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooperman Barnabas Medical Center, Livingston
  • Monmouth Medical Center, Long Branch
  • 他6件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649

A Study of CRD3874-SI in People With Leukemia

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (All protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07661095

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooperman Barnabas Medical Center, Livingston
  • Monmouth Medical Center, Long Branch
  • 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooper Hospital University Medical Center, Camden
  • Cooperman Barnabas Medical Center, Livingston
  • 他7件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Hackensack University Medical Center, Hackensack
  • Morristown Medical Center, Morristown
  • Jersey Shore Medical Center, Neptune City
  • 他4件
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • John Theurer Cancer Center at Hackensack UMC, Hackensack
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06824168

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Atlantic Health, Morristown
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Hackensack University Medical Center, Hackensack
  • Morristown Medical Center, Morristown
  • Jersey Shore Medical Center, Neptune City
  • 他3件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Hackensack University Medical Center, HMH, Hackensack
  • Morristown Medical Center, Morristown
被験者募集中第3相
29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Rutgers Biomedical and Health Sciences, New Brunswick
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788

A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)

  • MDA at Cooper University Health Care, Camden
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07771803

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

  • Atlantic Health, Morristown
被験者募集中第2/3相
18歳〜80歳 · 全性別 · 2026/08/05更新 · NCT06788756

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

  • Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
被験者募集中第2相
60歳以上 · 全性別 · 2026/07/17更新 · NCT07392242

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Hackensack University Medical Center, Hackensack
  • Robert Wood Johnson/Cancer Institute of New Jersey, New Brunswick
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Memorial Sloan Kettering Monmouth, Middletown
  • Memorial Sloan Kettering Bergen, Montvale
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT05756777

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
被験者募集中第1相
1歳以上 · 全性別 · 2026/06/22更新 · NCT06017258

A Study of Revumenib and Mezigdomide in People With Leukemia

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/06/22更新 · NCT07356154

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/06/17更新 · NCT07011004

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • John Theurer Cancer Center / Hackensack University, Hackensack
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Atlantic Health, Morristown
  • Rutgers Cancer Institute of New Jersey, New Brunswick
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555

Phase IB/II of CPX-351 for Relapse Prevention in AML

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/23更新 · NCT04990102

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Hackensack University Medical Center, Hackensack
  • Rutgers Cancer Institute, New Brunswick
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/10更新 · NCT05748197

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/24更新 · NCT06773208

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。